ATTY. DOCKET NO. 6750-174-999 (305158-999172)

APPLICATION NO. 10/625,708

APPLICANT

Donald J. KYLE et al.

FILING DATE
July 24, 2003

GROUP 1624

OCT 0 5 7005 8

FREFERENCES CITED BY APPLICANT

(Us geveral stocts if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
INITIAL	A01	4,439,606	03/27/1984	De et al.	544	356	
- 17	A02	4,450,272	05/22/1984	Du et al.	544	357	-
	A03	5,039,680	08/13/1991	Imperato et al.	514	304	
	A04	5,075,341	12/24/1991	Mendelson et al.	514	282	
	A05	5,198,459	03/30/1993	Imperato et al.	514	397	_
	A06	5,232,934	08/03/1993	Downs	514	345	
	A07	5,430,033	06/04/1995	Cliffe et al.	514	254	
	A08	5,442,064	08/15/1995	Pieper et al.	· 544	360	
	A09	5,461,047	10/24/1995	Hansen Jr. et al.	514	211	
	A10	5,556,837	09/17/1996	Nestler et al.	514	21	
	A11	5,556,838	09/17/1996	Mayer et al.	514	25	
	A12	5,574,052	11/12/1996	Rose et al.	514	343	
	A13	5,607,936	05/04/1997	Chiang et al.	514	255	
	A14	5,756,504	05/26/1998	Bock et al.	514	252	·
	A15	5,762,925	06/09/1998	Sagen	424	93.7	
	A16	5,789,412	08/04/1998	Halazy et al.	514	255	
	A17	5,792,768	08/11/1998	Kulagowski et al.	514	255	
	A18	6,028,195	02/22/2000	Cho et al.	544	360	
	A19	6,109,269	08/29/2000	Rise et al.	128	898	
	A20	6,204,284	03/20/2001	Beer et al.	514	412	
	A21	6,329,395	12/11/2001	Dugar et al.	514	329	·
	A22	2003/0153596	08/14/2003	Suh et al.	514	311	
	A23	2003/0158188	08/21/2003	Lee et al.	514	228.2	
	A24	2003/0158198	08/21/2003	Lee et al.	514	241	
	A25	2003/0187023	10/02/2003	Kubo et al.	514	318	
	A26	2004/0106622	06/03/2004	Morie et al.	514	252.14	
	1					<u> </u>	
				1			

			FOREIGN	PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATIO
							YES	NO
<u>k</u> k	B01	WO 96/21648	07/18/1996	PCT				
T	B02	WO 98/00402	01/08/1998	PCT				
\top	B0:	WO 99/07672	02/18/1999	PCT				
\top	B04	WO 00/52001	09/08/2000	PCT			-	
	B0:	WO 02/05819	01/24/2002	PCT				
·¥		11		<u> </u>			NYJD: 1591	910.

AM Mu

10/14/2005

KN	B06	WO 02/16318	02/28/2002	PCT		
	B07	WO 03/022809	03/20/2003	PCT		
	B08	WO 03/062209	07/31/2003	PCT		
	B09	WO 03/068749	08/21/2003	PCT		
	B10	EP 1 122 242 A1	0808/2001	EP		
	B11	JP 10-007572	01/13/1998	Japan	XX	x
	B12	JP 2001-328938	11/27/2001	Japan	XX	x
1	B13	JP 2001-261657	09/26/2001	Japan	XX	x

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
KN	C01	Berkow et al., The Merck Manual of Medical Information 1997; 345-350
1	C02	Berkow et al., The Merck Manual of Medical Information 1997; 352-355
	C03	Berkow et al., The Merck Manual of Medical Information 1997; 496-500
	C04	Berkow et al., The Merck Manual of Medical Information 1997; 525-526
	C05	Berkow et al., The Merck Manual of Medical Information 1997; 528-530
	C06	Berkow et al., The Merck Manual of Medical Information 1997; 530-532
	C07	Berkow et al., The Merck Manual of Medical Information 1997; 631-634
	C08	Chiamulera et al., "Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Mice," Nat Neurosci 2001; 4(9):873-874
	C09	Cooke, "Glycopyrrolate in Bladder Dysfunction," S Afr Med J 1983; 63:3
	C10	Di Marzo et al., "Endovanilloid Signaling in Pain," Curt Opin Neurobiol 2002; 12:372-379
	C11	Dogrul et al., Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, a Metabotropic Glutamate Receptor (mGluR ₅) Antagonist, In Experimental Neuropathic Pain in Rats," Neurosci Lett 2000; 292(2):115-118
	C12	Foley, "Pain" Cecil Textbook of Medicine 1996; 100-107
	C13	Fundytus et al., "Antisense Oligonucleotide Knockdown of mGluR ₁ Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation," Pharmacol Biochem Behav 2002; 73:401-410
	C14	Fundytus et al., "In Vivo Antinociceptive Activity of Anti-rat mGluR ₁ and mGluR ₅ Antibodies in Rats," NeuroReport 1998; 9:731-735
	C15	Fundytus et al., "Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR ₁) Alleviates Pain and Restores Opioid Efficacy After Nerve Injury in Rats," Br J Pharmacol 2001; 132:354-367
	C16	Fundytus, "Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain," CNS Drugs 2001; 15:29-58
	C17	Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (J. Hardman and L. Limbird eds., 9th ed. 1996)
	C18	Herzog et al., "Urinary Incontinence: Medical and Psychosocial Aspects," Annu Rev Gerontol Geriatr 1989; 9:74-119
	C19	Kwak et al., "A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance," Neuroscience 1998; 84:619-626
	C20	Levin et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder," J Urol 1982; 128:396-398
	C21	Mirakhur et al., "Glycopyrrolate: Pharmacology and Clinical Use," Anaesthesia 1983; 38:1195-1204
	C22	Ohkubo et al., "The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol," J. Dent Res Apr 1997; 76(4):848-851
	C23	Ossowska et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian- like Effects in Rats," Neuropharmacology 2001; 41:413-420
	C24	Pan et al., "Soluble Polymer-Supported Synthesis of Arylpiperazines," Tett Lett 1998; 39:9505-9508
	C25	Resnick, "Urinary Incontinence," Lancet 1995; 346:94-99
	C26	Spooren et al., "Novel Allosteric Antagonists Shed Light on mGluR ₅ Receptors and CNS Disorders," Trends Pharmacol Sci 2001; 22(7):331-337
	C27	Tatarczyska et al., "Potential Anxiolytic- and Antidepressant-like Effects of MPEP, a Potent, Selective and Systemically Active mGlu5 Receptor Antagonist, "Br J Pharmacol 2001; 132(7):1423-1430
	C28	Urban et al., "In Vivo Pharmacology of SDZ 249-665, A Novel, Non-pungent Capsaicin Analogue," Pain 2000; 89:65-74

A My Mu

10/14/2005 NYJD: 1591910.1

Kn	C29	Walker et al., "Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. 1. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain," Neuropharmacology 2000 40:1-9
KH	C30	Wein, "Pharmacology of Incontinence," Urol Clin North Am 1995; 22(3):557-577
KN	C31	Wu et al., "Multiple Sensory and Functional Effects of Non-phenolic Aminodimethylene Nonivamide: An Approach to Capsaicin Antagonist," Gen Pharmac 1996; 27(1):151-158
EXAMINER		J M M DATE CONSIDERED 10/14/2005
		reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not y of this form with next communication to applicant.